mobocertinib
EGFR exon 20 mutant inhibitor, oral once-daily FDA-approved for EGFR ex20+ NSCLC from cellular screening + SBDD Bioorg. Med. Chem. Lett., 21 November 2022 ARIAD/Takeda, Cambridge, MA
Molecules of the Month - November 2022
Molecules of the Month
- ervogastat
- PTC258
- sirpiglenastat
- ENT-01
- mobocertinib
- compound 29
- compound 27 (CTPS1)
- compound 14d
- TDI-11861
- EG-011